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ABSTRACT
Reduced-intensity allogeneic hematopoietic stem cell transplantation (alloHSCT), which typically results in mixed
chimerism initially after transplantation, has had limited efficacy in chemotherapy-refractory lymphomas. We
hypothesized that the rapid establishment of complete donor chimerism would potentiate a graft-versus-lymphoma
effect. Fifteen patients with chemotherapy-refractory lymphoma initially received induction with a conventional
chemotherapy regimen (etoposide, prednisone, vincristine, cyclophosphamide, adriamycin, fludarabine [EPOCH-F]) to
deplete host T cells and provide disease control prior to alloHSCT. Patients then received conditioning with
fludarabine and cyclophosphamide followed by alloHSCT from HLA-matched siblings. Graft-versus-host disease
prophylaxis consisted of cyclosporine alone. EPOCH-F resulted in 73% of patients having partial responses or stable
disease. EPOCH-F depleted host CD4 T cells from a median of 235 cells/L to 56 cells/L. Fourteen patients
underwent alloHSCT, and all had >95% donor engraftment by day 14 after transplantation. The incidence of Grade
II to III acute graft-versus-host disease was 71%. There were two therapy-related deaths. There were 8 partial
responses and 3 complete responses (CRs) at day 28. Five additional CRs were observed at day 100 without
withdrawal of cyclosporine or donor lymphocyte infusion. The rate of CRs for all 15 patients was 60%. The 1-year
progression-free survival rate from time of study entry is 67% with only 1 relapse among 9 CRs. At a median potential
follow-up of 28 months, the overall survival rate is 53%. These data demonstrate that a potent and durable
graft-versus-lymphoma effect can occur against chemotherapy-refractory lymphomas and suggest that this effect may
be associated with rapid, complete donor chimerism after reduced-intensity alloHSCT.
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INTRODUCTION
Patients with chemotherapy-refractory lymphomas who fail to
enter a remission with initial chemotherapy (primary refractory)
or to achieve a partial response to second-line or “salvage”
chemotherapy at relapse (secondary refractory) have a very poor
prognosis [1-3]. High-dose therapy and autologous hematopoi-
etic stem cell transplantation (autoHSCT) appear to beneﬁt
only a small minority of patients with primary or secondary
refractory B-cell lymphomas [4-6]. As such, there is a need for
novel, alternative therapies in this poor prognostic group.
Allogeneic hematopoietic stem cell transplantation (al-
loHSCT), using myeloablative conditioning regimens, may pro-
vide durable remissions in patients with refractory lymphomas
[7-11]. However, the applicability of alloHSCT has been se-
verely limited by treatment-related morbidity and mortality in
older adults and in younger patients who have received extensive
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prior therapy or have a less than optimal performance status,
which often negate the beneﬁcial effects of alloHSCT [10-13].
Attempts to reduce treatment-related mortality have been made
by using nonmyeloablative or reduced-intensity (RI) condition-
ing regimens that are adequately immunosuppressive to consis-
tently permit the engraftment of allogeneic stem cells from
HLA-matched siblings [14-18]. RI alloHSCT relies either pri-
marily or almost exclusively on a graft-versus-lymphoma (GVL)
effect to eliminate lymphoma. Speciﬁcally, this strategy typically
produces a state of mixed chimerism, which may compromise
the GVL effect, and often necessitates the removal of immuno-
suppressive agents, such as cyclosporine (CsA), and/or the infu-
sion of additional donor lymphocytes to convert the recipient to
full donor lymphoid chimerism [17-19]. The efﬁcacy of RI
alloHSCT has been limited in lymphomas that are refractory,
bulky, or of advanced histology [20-27]. We hypothesized that
establishment of rapid and complete donor chimerism after RI
alloHSCT would enhance the GVL effect in patients with
chemotherapy-refractory lymphomas.
Based on a murine F1-into-parent model of marrow graft
rejection [28], we designed a protocol that uses repeated cycles
of chemotherapy at conventional doses to deplete host T cells to
a level that might limit mixed chimerism after RI alloHSCT.
The primary aim of this study was to determine whether this
sequential chemotherapy approach, which emphasizes the role
of host immune ablation, would permit rapid complete donor
chimerism after alloHSCT in the treatment of refractory B-cell
lymphomas.
PATIENTS AND METHODS
Eligibility Criteria
Patients with non-Hodgkin’s lymphoma (NHL) or chronic
lymphocytic leukemia that was primary or secondary chemo-
therapy-refractory or had progressed after autoHSCT were el-
igible for this study. Diagnosis was conﬁrmed by the National
Cancer Institute (NCI) Laboratory of Pathology using the Re-
vised European-American Lymphoma (REAL) classiﬁcation
[29]. Age between 16 and 75 years, Karnofsky performance
status of 70%, serum bilirubin 2.5 mg/dL, hepatic transami-
nases 2.5 times normal, creatinine clearance 60 mL/min,
pulmonary diffusion capacity 50% of predicted, and left ven-
tricular ejection fraction of 50% were additional eligibility
criteria. All patients had an acceptable 5 of 6 or 6 of 6 HLA-
matched sibling donor who consented to serve as an allogeneic
blood stem cell donor. This protocol, CC 99-C-0143, was ap-
proved by the NCI Institutional Review Board, and informed
written consent was obtained from each patient and their re-
spective donor.
Induction Chemotherapy
To reduce circulating T cells while providing tumor control
prior to transplantation, patients received an induction regi-
men—etoposide, prednisone, vincristine, cyclophosphamide,
adriamycin, ﬂudarabine (EPOCH-F)—that combines ﬂudara-
bine with the EPOCH regimen, which has been shown to be
active in refractory lymphomas [30]. Patients received a mini-
mum of 1 and a maximum of 3 cycles of EPOCH-F, which was
administered every 21 days. Patients received EPOCH-F until
their CD4 count was 50 cells/L or until progressive disease
occurred after any given cycle. EPOCH-F consisted of a 72-
hour (days 1 to 3) continuous infusion of etoposide (50 mg/m2/
d), doxorubicin (10 mg/m2/d), vincristine (0.5 mg/m2/d), cyclo-
phosphamide (600 mg/m2) intravenously (IV) on day 4,
prednisone 60 mg/m2/d orally on days 1 to 4, and ﬂudarabine
(25 mg/m2/d) IV on days 1 to 3. Filgrastim (granulocyte colony-
stimulating factor) was given subcutaneously 10 g/kg/d from
day 5 until an absolute neutrophil count (ANC) 1000 cells/L
for 2 consecutive days.
Conditioning Regimen
The conditioning regimen consisted of ﬂudarabine (30 mg/
m2/d) and cyclophosphamide (1200 mg/m2/d) administered
concomitantly IV on days -6, -5, -4, and -3 prior to transplan-
tation. Sodium 2-mercaptoethanesulfonate (Mesnex, Bristol-
Myers Squibb/Baxter Healthcare, Deerﬁeld, IL) was given on
days -6 to -3 by continuous IV infusion at a dosage of 1200
mg/m2/d.
Blood Stem Cell Mobilization, Collection, and
Transplantation
Hematopoietic stem and progenitor cells were mobilized
with ﬁlgrastim at 10 g/kg/d. Apheresis was performed on days
5 and 6 of ﬁlgrastim administration using the Fenwal CS3000
Plus cell separator (Baxter Healthcare Corporation, Deerﬁeld,
IL). Fifteen to 25 L of blood were processed per procedure to
achieve a target dose of 4.0  106 CD34 cells/kg (recipient
weight). All apheresis products were cryopreserved in Plasma-
lyte A (Baxter) with 4% human serum albumin, 5% dimethyl
sulfoxide (Research Industries, Salt Lake City, UT), and 6%
Pentastarch (B. Braun, Irvine, CA), and were stored in liquid
nitrogen. Cells were thawed and infused on day 0. Filgrastim
was administered daily at 10 g/kg from the day of alloHSCT
until the ANC was 5000 cells/L for 3 consecutive days.
Graft-versus-Host Disease Prophylaxis
Patients received CsA alone as graft-versus-host disease
(GVHD) prophylaxis. CsA was initiated on day -1 of the trans-
plantation and was adjusted to maintain trough serum CsA levels
of 150 to 250 ng/mL for the ﬁrst 100 days after alloHSCT and
then tapered between day 100 and 180, depending on the
presence or absence of GVHD.
Supportive Care
Following both induction chemotherapy and transplanta-
tion, infection prophylaxis consisted of trimethoprim/sulfame-
thoxazole, acyclovir, and ﬂuconazole. To avoid potential drug
interactions with vincristine, ﬂuconazole was held during the
administration of EPOCH-F. Trimethoprim/sulfamethoxazole
was given for the week prior to stem cell transplantation, and
then was resumed each weekend day after engraftment.
Quantitation of Host Immune T-Cell Depletion
The absolute number of circulating host CD4 and CD8
T cells were determined at study entry, after day 17 of each cycle
of EPOCH-F, and on the day of stem cell infusion (day 0). Flow
cytometry was performed in a Clinical Laboratory Improvement
Amendments–certiﬁed laboratory (Science Applications Inter-
national Corporation, Frederick, MD). The percentage of
CD45 lymphocytes expressing CD3CD4 or CD3CD8
markers was determined. Complete blood cell counts and dif-
ferentials, performed in the National Institutes of Health Clin-
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ical Center Laboratory, were then used to calculate the absolute
number of CD4 and CD8 T cells per L of blood.
Chimerism Evaluation
Chimerism analysis was performed using the variable num-
ber tandem repeats–polymerase chain reaction method in a
Clinical Laboratory Improvement Amendments–certiﬁed labo-
ratory at the Blood Center of Southeastern Wisconsin. Chimer-
ism was determined at day 14, day 28, day 56, day 100,
and day 365 posttransplantation on total peripheral blood
mononuclear cells. In some cases, chimerism was additionally
determined on posttransplantation samples enriched for my-
eloid (CD15 or CD33) or T-lymphoid (CD3) subsets. My-
eloid or lymphoid cell subset enrichment was by positive selec-
tion using either magnetic beads (Miltenyi, Inc., Auburn, CA) or
rosette technique (Stem Cell Technologies, Inc., Vancouver,
Canada).
Definitions of Response
Disease response was assessed according to the recommen-
dations of the NCI Sponsored International Working Group for
the standardization of response criteria for NHL [31]. Stable
disease was deﬁned as no more than a 25% increase or a 25%
decrease in the sum products of the greatest diameters of lymph
nodes and nodal masses. All patients underwent a computerized
axial tomography of the chest, abdomen, and pelvis and a bone
marrow examination prior to study entry, after each cycle of
EPOCH-F, and at day28, day100,6 months,9 months,
12 months, and thereafter annually unless otherwise clinically
indicated. Single-photon emission computed tomography was
used to assess questionable abnormalities.
Statistical Analysis
Toxicities were deﬁned using the NCI Toxicity Criteria
Version 2.0. Progression-free survival (PFS) was calculated from
the date the patient enrolled in the study, as well as the date of
transplantation, until the date that the patient progressed or had
progression censored at the date of death or last follow-up.
Survival durations were calculated from enrollment date until
date of death or last follow-up. The probabilities of survival or
PFS as a function of time were calculated using the Kaplan-
Meier method [32]. Associations between categorical parameters
and response were made using the Jonckheere-Terpstra trend
test or Cochran-Armitage trend test depending on whether both
variables or only one variable was ordered [33,34]. In addition,
changes in response at set time points in the treatment course
were compared with the initial response using a marginal ho-
mogeneity test, which is an extension of McNemar’s test for
paired categorical data [35]. In each case, an exact method was
used due to the small number of patients evaluated. All reported
P values are two-tailed.
RESULTS
Patient Characteristics
Fifteen patients were enrolled between July 1999 and Oc-
tober 2000 (Table 1). The median patient age was 49 years
(range: 33 to 63 years). Histologies included large cell B-cell
lymphoma in 6, follicular B-cell lymphoma in 4, mantle cell
lymphoma in 3, and chronic lymphocytic lymphoma in 2, in-
cluding 1 that had transformed to prolymphocytic leukemia
[29]. Thirteen patients had disease that was refractory to the last
administered regimen, including 3 patients with primary refrac-
tory NHL. One patient with mantle cell lymphoma was enrolled
following relapse after “hyper–cyclophosphamide, vincristine,
doxorubicin, dexamethasone” [36]. The median number of prior
therapies was 3 (range: 1 to 6), and 3 patients had received a
prior autoHSCT.
Host Immunoablation
The median CD4, CD8, and natural killer cell numbers
prior to treatment were 235 (range: 13 to 1697), 161 (range: 13
to 934), and 69 (range: 23 to 283) cells/mL, respectively (Table
1). Patients received a median of 2 cycles (range: 1 to 3) of
Table 1. Patient Characteristics
Patient
No. Age Sex Histology
No. of
Prior Tx
Prior
AutoHSCT
Disease Status at
Study Entry
CD4/CD8 #
Pre-EPOCH-F
CD4/CD8 #
Post-EPOCH-F
1 44 M MC 3 Yes Refrac relapse 74/48 16/5
2 38 M FCC 5 Yes Refrac relapse 283/160 78/25
3 41 F DLC 4 No Refrac relapse 118/156 49/58
4 33 F Thymic DLC 2 No Primary refract 235/406 26/12
5 34 F DLC 3 No Refrac relapse 13/13 12/12
6 51 M MC 1 No Untreated relapse 365/599 56/104
7 51 M CLL (PLL) 6 No Refrac relapse 1697/849 48/2
8 39 M MC 3 No Refrac relapse 267/934 141/309
9 63 F FCC 4 No Refrac relapse 196/302 77/102
10 61 F DLC 3 Yes Refrac relapse 172/124 54/32
11 39 F DLC 3 No Primary refract 285/462 102/68
12 49 F FCC 3 No Sens relapse 91/51 62/40
13 52 M CLL 4 No Refrac relapse 522/161 165/22
14 57 F FCC 2 No Refrac relapse 439/248 96/31
15 56 M DLC 1 No Prim refract 141/39 10/2
Tx indicates treatment; CMV, cytomegalovirus; AutoHSCT, autologous hematopoietic stem cell transplant; #, cells/mL; EPOCH-F, etoposide/
prednisone/vincristine/cyclophosphamide/adriamycin/ﬂudarabine; M, male; F, female; MC, mantle cell; Refrac relapse, refractory relapse; FCC,
follicular center cell; DLC, diffuse large cell; Primary refract, primary refractory; PLL, prolymphocytic leukemia; CLL, chronic lymphocytic
leukemia; , positive serology; , negative serology; NA, not available.
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EPOCH-F, and the median CD4 and CD8 cell numbers
after EPOCH-F were of 56 (range: 10 to 165; P  .03) and 31
(range: 2 to 309; P  .01) cells/mL, respectively. Circulating
natural killer cell numbers (median , 90; range: 21 to 413) were
not signiﬁcantly (P  .76) reduced after EPOCH-F. Three
patients proceeded to transplantation with CD4 counts 50
cell/mL, despite receiving less than 3 cycles of EPOCH-F, due
to progressive disease.
Hematopoietic Recovery
Fourteen patients proceeded to transplantation and all were
evaluable for hematopoietic recovery and engraftment. Patients
received a median of 8.08  106 CD34 cells/kg (range: 4.55 to
12.8  106) and 3.50  108 CD3 cells/kg (range: 2.12 to
7.85  108). The median times to an ANC 500, 1000, and
5000  109/L were 9, 9, and 10.5 days, respectively. All but 1
patient achieved a platelet count 100  103/L. The median
times to platelet counts of 20, 50, and 100 103/L were 9.5, 13,
and 15 days, respectively, independent of platelet transfusion.
Donor Lymphoid and Myeloid Engraftment
All 14 patients demonstrated evidence of near complete
donor chimerism at day 14 posttransplantation; the median
total mononuclear cell donor chimerism was 98% (Table 2).
Lymphoid chimerism was complete and sustained as measured
on days 28 through 365. No patient received a donor lym-
phocyte infusion.
Toxicity
Induction Chemotherapy with EPOCH-F. A total of 31 cycles
of EPOCH-F was administered. The regimen was well tolerated
with only 3 episodes of neutropenic fever. Two patients devel-
oped active infections prior to alloHSCT, 1 with a respiratory
syncitial virus pneumonitis, which resolved with ribavirin, and 1
with a pulmonary aspergillosis, which resolved with amphoter-
icin. The case of pulmonary aspergillosis progressed in the
central nervous system, but responded to therapy with voricon-
azole [37].
Conditioning Regimen with Fludarabine and Cyclophosphamide.
Patients experienced minimal to no mucositis, and there were no
cases of veno-occlusive disease. The most signiﬁcant toxicity was
engraftment syndrome, deﬁned by the occurrence of pulmonary
inﬁltrates, third-spacing of ﬂuids, and fever, which was observed
in 6 patients (43%) [38]. Patients with engraftment syndrome
received systemic corticosteroids (methylprednisolone 1 g/d in
divided doses). All patients had complete resolution of symp-
toms, generally within 24 to 72 hours after initiation of corti-
costeroids, which were then tapered rapidly to discontinuation
over a 1- to 2- week period.
Acute and Chronic GVHD
Fourteen patients were evaluable for acute GVHD (Table
2), and 10 (71%) patients developed Grade II to III acute
GVHD. There were no cases of Grade IV acute GVHD. The
median time to onset of acute GVHD was 31 days (range: 11 to
84 days). In 3 of the 5 patients with Grade III acute GVHD, the
onset of disease occurred after discontinuation of CSA on ac-
count of either toxicity (n 2) or progressive lymphoma (n 1).
Seven of 13 (54%) evaluable patients developed chronic GVHD.
Two patients had limited chronic GVHD, and 5 patients had
extensive chronic GVHD. The 2 treatment-related mortalities
(gastrointestinal bleed and Aspergillus infection) were directly
related to GVHD, as both patients were receiving corticoste-
roids at the time of death.
Table 2. Posttransplantation Outcome
Patient
No.
Engraftment (VNTR-PCR Analysis of Total MNC) GVHD
Current Status After
AlloHSCT
Day
14
Day
28
Day
56
Day
100
Day
365 Acute Chronic
1 98% 99% 100% 100% 100% Gr II Extensive Alive 30 mo, isolated
relapse at 24 mo
2 100% 100% 100% — NE Gr III Extensive Died d 153 from
gastrointestinal bleed
(GVHD)
3 98% 100% 100% 100% 100% Gr II Limited Alive 26 mo, CR
4 100% 100% 100% 100% NE Gr II None Died d 134 from PD
5 98% 100% 100% 100% 100% Gr I Extensive Alive 26 mo, CRu
6 100% 100% 100% 100% 100% Gr III None Alive 23 mo, CR
7 95% 95% — 100% NE Gr III Extensive Died d 236 from
infection (Aspergillus)
with SD
8 95% 80%* 75%* 75% 100% Gr II None Alive 21 mo, CR
9 95% 98%* 100% 100% NE Gr I None Died d 120 from PD
10 100% 100%* NE — — Gr III NE Died d 73 from PD
11 100% 99% 100% 100% NE Gr III None Died d 191 from PD
12 100%* 100% 100% 100% 100% Gr I Limited Alive 17 mo, CRu
13 99%* 100% 100% 100% 100% Gr II Extensive Alive 16 mo, CRu
14 100%* 100%* 100% 100% 100% Gr I None Alive 15 mo, CRu
MNC indicates mononuclear cells; GVHD, graft-versus-host disease; mo, months; Gr, grade; CR, complete response; CRu, complete response
undetermined; PD, progressive disease; SD, stable disease; NE, non-evaluable.
*Complete (x  98%) lymphoid chimerism by CD3 separation.
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Outcome
All patients received at least 1 cycle of EPOCH-F. After
receiving EPOCH-F, 5 patients achieved a partial response,
including 3 patients whose disease was previously chemother-
apy-refractory. Six patients had stable disease, and 4 patients had
progressive disease.
Fourteen patients proceeded to alloHSCT. One patient
with primary refractory disease (patient 15) progressed during
EPOCH-F and did not proceed to alloHSCT. Response was
determined at day28 after alloHSCT to evaluate the cytotoxic
effects of the conditioning regimen. The overall response at day
28 was 73% with 3 complete responses (CRs) and 8 partial
responses. Between day 29 and day 100 posttransplantation
5 additional patients had a CR. One patient with stable disease
at day 28 and a partial response at day 100, subsequently
achieved a CR at 6 months after alloHSCT. All 3 patients, who
had progressed on EPOCH-F and achieved a partial response at
day 28, had progressive disease at day 100. The overall
response rate for this treatment approach, on an intent-to-treat
basis, was 80% with 9 CRs and 3 partial responses. At a median
potential follow-up of 28 months (range: 19 to 37) from the time
of study entry, the PFS rate is 67% at 1 year on an intent-to-
treat analysis (Figure 1A). The overall survival rate is 53%
(Figure 1B). Of the 9 patients who made it to CR (8 by day100
and 1 by 6 months), all were still without progression from 20 to
31 months after transplantation, except for 1 patient who pro-
gressed 26.5 months after transplantation.
There was no signiﬁcant association of response to the
number of previous regimens, including prior autoHSCT, or
histology. There was a strong association between response to
EPOCH-F and response after alloHSCT. All 5 patients who
achieved a partial response to EPOCH-F eventually achieved a
CR after alloHSCT, as compared with only 4 of 9 patients who
had stable or progressive disease to EPOCH-F (P  .0005).
There was no association between the development of GVHD
and best response (P  .05).
DISCUSSION
In contrast to a strategy of establishing mixed chimerism, we
chose to achieve rapid, complete donor chimerism through the
administration of sequential, immunoablative chemotherapy.
We chose this strategy for two reasons. First, the available
medical literature suggests that an optimal graft-versus-tumor
effect may not be observed until complete lymphoid chimerism
is achieved [24,25,39]. Second, we targeted patients with aggres-
sive, chemotherapy-refractory lymphomas. A strategy of estab-
lishing mixed chimerism may be adequate for less aggressive,
relatively indolent lymphomas [40]. The proliferation of more
aggressive lymphomas, however, such as mantle cell or large
B-cell NHL, may outpace the establishment of complete donor
chimerism and subsequent GVL effects. One tactic that pro-
vides both signiﬁcant anti-tumor activity and rapid, complete
donor chimerism is high-dose therapy and autoHSCT prior to
RI alloHSCT [41]. We elected to administer immunoablative
chemotherapy at conventional doses and, adopting a tactic used
by investigators at M.D. Anderson Cancer Center, used chemo-
therapeutic agents that had activity against the disease being
treated [26,27,40]. The EPOCH-F regimen resulted in a de-
crease in circulating T lymphocytes in all patients and provided
disease control in the majority of patients. The effectiveness of
this strategy on engraftment was realized as all patients had
complete lymphoid chimerism by day 28 posttransplantation.
The fact that all patients had complete engraftment does not
permit us to make any ﬁrm conclusions relative to our hypoth-
esis; however, an ongoing clinical trial with T-cell–depleted
allografts strongly suggests that host T-cell depletion before
transplantation is important relative to the achievement of com-
plete donor chimerism [42].
Although the patient numbers are small, the CRs are rela-
tively high in this select group of patients with refractory lym-
phomas, who were all ineligible for autoHSCT. These re-
sponses could partially be attributed to the conditioning
regimen, which contained agents that are active against lympho-
mas and were used at higher than conventional doses [43].
However, the majority of CRs occurred between day 28 and
day100. Delayed responses, such as these, have been observed
after high-dose cytotoxic chemotherapy and autologous stem
cell transplantation. In light of the fact that all of these patients
had received extensive prior therapy, however, that the majority
had less than a partial response to EPOCH-F and that responses
have been sustained suggest that these responses are at least
partially attributable to a GVL effect [44]. The contributions of
this signiﬁcant dose of cyclophosphamide, however, as well as
ﬂudarabine, can not be dismissed. These results are in contrast
to other reports of RI alloHSCT for the treatment of lympho-
mas, where responses were typically delayed and did not occur
until withdrawal of immune suppression, and/or required donor
lymphocyte infusions [17,18]. This treatment strategy also was
associated with a high incidence of clinically signiﬁcant acute
and chronic GVHD. Although there was not a direct correlation
between the development of GVHD and response, all complete
responders had some form of GVHD. It should be noted that in
3 patients with progressive disease GVHD did not occur until
removal of CsA to permit a GVL effect, but this tactic was
unsuccessful. It also should be noted that the 2 treatment-related
mortalities were indirectly related to GVHD because they were
clearly related to chronic corticosteroid administration. Al-
though direct comparisons can not be made to previous reports,
these data demonstrate that complete and durable responses can
occur after RI alloHSCT in patients with chemotherapy-refrac-
tory disease [45].
These results support our hypothesis that rapid, complete
donor engraftment can result in high response rates for relapsed,
refractory B-cell lymphomas. Responses were observed in more
advanced NHL, such as large cell and mantle cell NHL; how-
ever; it is not clear whether this strategy is necessary in patients
with more “indolent” disease [40]. Also, the amount of prior
cytotoxic therapy may be adequately immunosuppressive to re-
sult in engraftment kinetics similar to the results observed in this
study. A strategy of sequential, immunoablative chemotherapy
with activity against lymphomas can result in adequate disease
control and rapid, complete donor engraftment. The engraft-
ment results were consistent, and this strategy does not require
the relatively precarious management of mixed chimerism re-
quiring withdrawal of immune suppression or the infusion of
additional donor lymphocytes [15,17,18]. The establishment of
rapid donor chimerism more closely reﬂects the engraftment
kinetics associated with “traditional,” myeloablative alloHSCT
while avoiding early toxicities associated with myeloablative
conditioning regimens. Similar to myeloablative transplanta-
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tions, however, signiﬁcant toxicities persist primarily in the form
of GVHD. The decision to use myeloablative, RI, or nonmy-
eloablative allogeneic transplantation for lymphomas should
take into account disease status, histology, and degree of prior
therapy. Immunoablative strategies that provide disease control
and result in rapid complete lymphoid chimerism should be
considered in the use of RI alloHSCT for patients with ad-
vanced, refractory B-cell lymphomas.
REFERENCES
1. Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl
J Med. 1993;328:1023-1030.
2. Lichtman SM, Niedzwiecki D, Barcos M, et al. Phase II study of
infusional chemotherapy with doxorubicin, vincristine and etopo-
side plus cyclophosphamide and prednisone (I-CHOPE) in resistant
diffuse aggressive non-Hodgkin’s lymphoma: CALGB 9255. Can-
cer and Leukemia Group B. Ann Oncol. 2000;11:1141-1146.
Figure 1. (A) PFS for all 15 patients with B-cell lymphomas enrolled in the study. (B) Overall survival for all 15 patients with B-cell lymphomas
enrolled in the study.
Reduced-Intensity Allogeneic HSCT for NHL
167BB&MT
3. Younes A, Preti HA, Hagemeister FB, et al. Paclitaxel plus topote-
can treatment for patients with relapsed or refractory aggressive
non-Hodgkin’s lymphoma. Ann Oncol. 2001;12:923-927.
4. Prince HM, Imrie K, Crump M, et al. The role of intensive therapy
and autologous blood and marrow transplantation for chemother-
apy-sensitive relapsed and primary refractory non-Hodgkin’s lym-
phoma: identiﬁcation of major prognostic groups. Br J Haematol.
1996;92:880-889.
5. Nademanee A, Molina A, Dagis A, et al. Autologous stem-cell
transplantation for poor-risk and relapsed intermediate- and high-
grade non-Hodgkin’s lymphoma. Clin Lymphoma. 2000;1:46-54.
6. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and
autologous bone marrow transplantation after failure of conven-
tional chemotherapy in adults with intermediate-grade or high-
grade non-Hodgkin’s lymphoma. N Engl J Med. 1987;316:1493-
1498.
7. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic synge-
neic and autologous marrow transplantation for Hodgkin’s disease:
the 21-year Seattle experience. J Clin Oncol. 1993;11:2342-2350.
8. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a
graft-versus-lymphoma effect associated with allogeneic bone mar-
row transplantation. Blood. 1991;77:649-653.
9. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allo-
geneic bone marrow transplantation for non-Hodgkin’s lymphoma:
a case-controlled analysis of the European Bone Marrow Transplant
Group registry data. J Clin Oncol. 1992;11:1690-1695.
10. Van Besien KW, Rakesh CM, Giralt SA, et al. Allogeneic bone
marrow transplantation for poor-prognosis lymphoma: response,
toxicity and survival depend on disease histology. Am J Med. 1996;
100:299-307.
11. Ratanatharothorn V, Uberti J, Karanes C, et al. Prospective com-
parative trial of autologous versus allogeneic bone marrow trans-
plantation in patients with non-Hodgkin’s lymphoma. Blood. 1994;
84:1050-1055.
12. Verdonck LF, Dekker AW, Lokhorst HM, et al. Allogeneic versus
autologous bone marrow transplantation for refractory and recur-
rent low grade non-Hodgkin’s lymphoma. Blood. 1997;90:4201-
4205.
13. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone
marrow transplantation for low-grade lymphoma. Blood. 1998;92:
1832-1836.
14. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic
hematopoietic progenitor cells with purine analog-containing che-
motherapy: harnessing graft-versus-leukemia without myeloablative
therapy. Blood. 1997;89:4531-4536.
15. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell
transplantation and cell therapy as an alternative to conventional
bone marrow transplantation with lethal cytoreduction for the treat-
ment of malignant and nonmalignant hematologic diseases. Blood.
1998;91:756-763.
16. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction
of graft-versus-malignancy using ﬂudarabine-based nonablative
chemotherapy and allogeneic blood progenitor cell transplantation
as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-
2824.
17. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic
cell transplantation in older patients with hematologic malignancies:
replacing high-dose cytotoxic therapy with graft-versus-tumor ef-
fects. Blood. 2001;97:3390-3400.
18. Dey BR, McAfee S, Sackstein R, et al. Successful allogeneic stem
cell transplantation with nonmyeloablative conditioning in patients
with relapsed hematologic malignancy following autologous stem
cell transplantation. Biol Blood Marrow Transplant. 2001;7:604-612.
19. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte
infusions in 140 patients with relapsed malignancy after allogeneic
bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
20. van Besien KW, de Lima M, Giralt SA, et al. Management of
lymphoma recurrence after allogeneic transplantation: the relevance
of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19:
977-982.
21. Or R, Ackerstein A, Nagler A, et al. Allogeneic cell-mediated and
cytokine-activated immunotherapy for malignant lymphoma at the
stage of minimal residual disease after autologous stem cell trans-
plantation. J Immunother. 1998;21:447-453.
22. Wa¨sch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed
chimaerism and clinical outcome in 101 patients after myeloablative
conditioning regimens and allogeneic stem cell transplantation. Br J
Haematol. 2000;109:743-750.
23. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after
nonmyeloablative allogeneic peripheral blood stem cell transplan-
tation: full donor T-cell chimerism precedes alloimmune responses.
Blood. 1999;94:3234-3241.
24. Orsini E, Alyea EP, Chillemi A, et al. Conversion to full donor
chimerism following donor lymphocyte infusion is associated with
disease response in patients with multiple myeloma. Biol Blood Mar-
row Transplant. 2000;6:375-386.
25. Bader P, Beck J, Schlegel PG, et al. Additional immunotherapy on
the basis of increasing mixed hematopoietic chimerism after alloge-
neic BMT in children with acute leukemia: is there an option to
prevent relapse? Bone Marrow Transplant. 1997;20:79-81.
26. Mattsson J, Uzunel M, Brune M, et al. Mixed chimaerism is com-
mon at the time of acute graft-versus-host disease and disease
response in patients receiving non-myeloablative conditioning and
allogeneic stem cell transplantation. Br J Haematol. 2001;115:935-
944.
27. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction
of graft-versus-malignancy using ﬂudarabine-based nonablative
chemotherapy and allogeneic blood progenitor-cell transplantation
as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-
2824.
28. Petrus MJ, Williams JF, Eckhaus MA, et al. An immunoablative
regimen of ﬂudarabine and cyclophosphamide prevents fully MHC-
mismatched murine marrow graft rejection independent of GVHD.
Biol Blood Marrow Transplant. 2000;6:182-189.
29. Harris NL, Jaffe ES, Stein H, et al. A revised European-American
classiﬁcation of lymphoid neoplasms: a proposal from the Interna-
tional Lymphoma Study Group. Blood. 1994;84:1361-1392.
30. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy:
toxicity and efﬁcacy in relapsed and refractory non-Hodgkin’s lym-
phoma. J Clin Oncol. 1993;11:1573-1582.
31. Cheson BD, Horning SJ, Coifﬁer B, et al. Report of an international
workshop to standardize response criteria for non-Hodgkin’s lym-
phomas. NCI Sponsored International Working Group. J Clin
Oncol. 1999;17:1244-1253.
32. Kaplan E, Meier P. Non-parametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
33. Hollander M, Wolfe DA: Nonparametric Statistical Methods, 2nd
edition. New York, NY: John Wiley & Sons; 1999:189-269.
34. Margolin BH: Test for trends in proportions. In: Kotz S, Johnson
NL, eds. Encyclopedia of Statistical Sciences, Vol. 9. New York, NY:
John Wiley & Sons, Inc.; 1988:334-336.
M.R. Bishop et al.
168
35. Agresti A: Categorical Data Analysis. New York, NY: John Wiley &
Sons; 1990.
36. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and
high-dose methotrexate/cytarabine followed by stem-cell transplan-
tation: an active regimen for aggressive mantle-cell lymphoma.
J Clin Oncol. 1998;16:3803-3809.
37. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for
treatment of invasive fungal infections in patients with cancer.
Oncologist. 2000;5:120-135.
38. Spitzer TR. Engraftment syndrome following hematopoietic stem
cell transplantation. Bone Marrow Transplant. 2001;27:893-898.
39. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic
renal-cell carcinoma after nonmyeloablative allogeneic peripheral-
blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
40. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic
hematopoietic transplantation as adoptive immunotherapy for in-
dolent lymphoma: low incidence of toxicity, acute graft-versus-host
disease, and treatment-related mortality. Blood. 2001;98:3595-3599.
41. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by
nonmyeloablative immunosuppressive chemotherapy and allogeneic
peripheral-blood hematopoietic stem-cell transplantation as treat-
ment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma.
J Clin Oncol. 2000;18:3918-3924.
42. Bishop MR, Marchigiani D, Odom J, et al. Contribution of T cell
to engraftment: a comparison of T cell depleted vs. T cell replete
allografts after reduced-intensity conditioning. Blood. 2002;100:
621a.
43. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophos-
phamide with ﬁlgrastim support in patients with previously un-
treated indolent lymphoid malignancies. Blood. 2000;96:71-75.
44. Mandigers C, Meijerink JP, Raemaekers JM, et al. Graft vs
lymphoma effect of donor leukocyte infusion shown by real-time
quantitative PCR analysis of t(14;18). Lancet. 1998;352:1522-
1523.
45. Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral blood
stem cell transplantation using a ﬂudarabine-based low intensity
conditioning regimen for malignant lymphoma. Bone Marrow
Transplant. 2000;25:1021-1028.
Reduced-Intensity Allogeneic HSCT for NHL
169BB&MT
